Novo Nordisk Oral Semaglutide In PIONEER TEENS Trial In Children 10–17 With Type 2 Diabetes Achieved 0.83% Blood Sugar Reduction Vs Placebo At 26 Weeks

Benzinga Newsdesk www.benzinga.com Positive 91.6%